DAX23.795 +0,2%ESt505.511 +0,1%Top 10 Crypto15,58 -2,1%Dow46.316 +0,2%Nas22.591 +0,5%Bitcoin96.403 -1,1%Euro1,1725 ±-0,0%Öl67,06 -0,9%Gold3.815 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 DroneShield A2DMAA RENK RENK73 Lufthansa 823212 NVIDIA 918422 Wolfspeed A41JEH HENSOLDT HAG000 Novo Nordisk A3EU6F Tesla A1CX3T Alibaba A117ME Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown droht: DAX stabil -- Lufthansa: Piloten stimmen für Streiks -- Continental sieht Chance auf DAX-Verbleib -- Alibaba, Tilray, PUMA, Clara Technologies, Rüstungsaktien, Etsy im Fokus
Top News
ZertifikateAwards 2025/2026: Stimmen Sie ab und gewinnen Sie eine Reise nach Berlin! ZertifikateAwards 2025/2026: Stimmen Sie ab und gewinnen Sie eine Reise nach Berlin!
BVB-Aktie gefragt: Guirassy fit für Bilbao BVB-Aktie gefragt: Guirassy fit für Bilbao
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Viele Anleger entdecken Europa wieder als Investmentregion. Nutze die möglichen Chancen europäischer Aktien mit diesem günstigen ETF von Amundi!

Biomarin Pharmaceutical Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
45,84 EUR -0,07 EUR -0,15 %
FSE
54,02 USD +0,18 USD +0,33 %
BTT
Biomarin Pharmaceutical jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.8,81 Mrd. EUR

KGV29,78Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN924801

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09061G1013

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBMRN

Biomarin Pharmaceutical Aktien News

DatumMeistgelesen
PR NewswireBioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
PR NewswireBioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
PR NewswireBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
PR NewswireBioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
PR NewswireBioMarin Announces Governance Enhancements and Value Creation Initiatives
PR NewswireBioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
PR NewswireBioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
PR NewswireBioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
PR NewswireU.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
PR NewswireBioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
PR NewswireBioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
PR NewswireBioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
PR NewswireBioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
PR NewswireBioMarin to Participate in Three Upcoming Investor Conferences
PR NewswireBioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
PR NewswireBioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
PR NewswireBioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
PR NewswireU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
PR NewswireBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis ...
PR NewswireBioMarin to Participate in Bank of America 2023 Health Care Conference
PR NewswireBioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
PR NewswireBioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET
PR NewswireBioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Ach...
PR NewswireFDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
PR NewswireBioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
PR NewswireBioMarin to Participate in Three Investor Conferences in March
PR NewswireBioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
PR NewswireBioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023
PR NewswireBioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET
PR NewswireBioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Se...
PR NewswireBioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA
PR NewswireEuropean Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
RSSForm 4 1048477
PR NewswireBioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
RSSForm 4 1048477
RSSForm 10-Q 1048477
PR NewswireBioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
RSSForm 8-K 1048477
PR NewswireFDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
RSSCurrent report

Biomarin Pharmaceutical News

Biomarin Pharmaceutical News: auf dieser Seite finden Sie alle Biomarin Pharmaceutical News und Nachrichten zur Biomarin Pharmaceutical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biomarin Pharmaceutical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biomarin Pharmaceutical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.